Evidence map›Paper›PMID 31500964›Full record

ArticleVaccine2019

Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases.

Marcia A Blackman, Mark A Marchionni, John Gilly, Matthew Hepburn, Bruce L Innis, Alan D T Barrett, Kent E Kester, John R Mascola, James F Cummings, Thomas P Monath and 4 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marcia A BlackmanTrudeau Institute, Saranac Lake, NY, USA.
Mark A MarchionniTrudeau Institute, Saranac Lake, NY, USA.
John GillyTrudeau Institute, Saranac Lake, NY, USA.
Matthew HepburnBiological Technologies Office, Defense Advanced Research Projects Agency (DARPA), Arlington, VA, USA.
Bruce L InnisPATH, Washington, DC, USA.
Alan D T BarrettSealy Institute for Vaccine Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Kent E KesterSanofi Pasteur, Swiftwater, PA, USA.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
James F CummingsICON Government and Public Health Solutions, Washington, D.C., USA.
Thomas P MonathCrozet BioPharma LLC, Devens, MA, USA.
M Cristina CassettiVirology Branch, Division of Microbiology and Infectious Diseases, NIAID, NIH, Rockville, MD, USA.
Jerome H KimInternational Vaccine Institute, Seoul, South Korea.
Melanie SavilleCoalition for Epidemic Preparedness Innovations (CEPI), London, UK.
Stephen J ThomasDivision of Infectious Diseases, State University of New York, Upstate Medical University, Syracuse, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging and re-emerging infectious diseases are an expanding global threat to public health, security, and economies. Increasing populations, urbanization, deforestation, climate change, anti-vaccination movements, war, and international travel are some of the contributing factors to this trend. The recent Ebola, MERS-CoV, and Zika outbreaks demonstrated we are insufficiently prepared to respond with proven safe and effective countermeasures (i.e., vaccines and therapeutics). The State University of New York Upstate Medical University and the Trudeau Institute convened a summit of key opinion and thought leaders in the life sciences and biomedical research and development enterprises to explore global biopreparedness challenges, take an inventory of existing capabilities and capacities related to preparation and response, assess current "gaps," and prospect what could be done to improve our position. Herein we describe the summit proceedings, "Translational Immunology Supporting Biomedical Countermeasure Development for Emerging Vector-borne Viral Diseases," held October 2-3, 2018, at the Trudeau Institute in Saranac Lake, NY.

Indexed as

Communicable Diseases, EmergingDisease VectorsAnimalsClinical Trials as TopicDisease Models, AnimalDrug Evaluation, PreclinicalFemaleHumansInfluenza, HumanPregnancyPregnancy Complications, InfectiousTranslational Research, BiomedicalViral VaccinesVirus DiseasesZika Virus InfectionViral Vaccines

Identifiers

PMID31500964
PMCPMC7131820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.